ehealth radio network
Episodes
Friday Mar 04, 2022
Friday Mar 04, 2022
Karen Grinzaid, Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Karen Grinzaid discuss the following:
What is JScreen exactly? How did the service come to be called JScreen?
How did it start – tell us about the couple that came to you in Atlanta and their story about their child and the inspiration behind JScreen?
How does it work for people who want to get Screened?
How does the testing work with your own doctors?
Who helps you understand the results – is there a doctor or Genetic Counselor who talks to you about the screening?
How long from when you order the tests until you receive results?
How many tests can you get at one time? What are the costs?
Since you are a non-profit – can people or groups donate to your organization and how to do so?
Karen Grinzaid is Assistant Professor of Human Genetics and Executive Director of JScreen, a national online genetic disease screening program based out of Emory University School of Medicine. She has extensive experience in genetic counseling and testing, clinical care and clinical research. Karen is proud of JScreen’s success in helping couples across the U.S. have healthy babies and in giving people the information they need to help prevent the devastating effects of hereditary cancer.
Karen received her B.A. in Psychology from Northwestern University and her M.S. in Human Genetics from Sarah Lawrence College. She is certified in Genetic Counseling by the American Board of Medical Genetics/American Board of Genetic Counseling and as a Clinical Research Coordinator through the Association of Clinical Research Professionals.
About JScreen
JScreen is a national non-profit public health initiative dedicated to preventing genetic diseases and hereditary cancer. Headquartered in Atlanta at Emory University School of Medicine, the JScreen initiative provides convenient at-home access to cutting-edge genetic testing technology, patient education and genetic counseling services. JScreen believes the combination of education, access to premier genetic screening technologies and personalized, confidential support are the keys to preventing devastating diseases.
Although both JScreen and direct to consumer DTC companies allow participants to screen at home. JScreen’s program is led by medical professionals at an academic medical center and provides medical grade testing that is used in doctor’s offices, as well as specialized genetic counseling via tele-health.
Website: https://www.jscreen.org
Social Media Links: Facebook: @MyJScreen Instagram: @GetJScreened Twitter: @MyJScreen
Saturday Nov 13, 2021
Saturday Nov 13, 2021
Michael Gorton, the CEO and founder of Recuro Health and Founding CEO and Chairman of Teladoc joins eHealth Radio and the Healthcare and Health News Channels. Recuro Health is an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health outcomes approach.
Listen to interview with host Eric Michaels and guest Michael Gorton discuss the following:
How did Recuro start?
Tell us more about what Recuro offers as a digital health solutions company?
What makes Recuro different from other digital health companies?
Who are your services available to?
What role will digital health play post-pandemic as patients return to in-person doctor’s appointments?
Can you tell our viewers more about your Covid at-home lab testing kits?
How does digital health enhance healthcare in rural and underserved communities?
Can you speak more on Recuro’s approach to behavioral and mental health? What kind of digital health solutions does Recuro offer?
A quintessential entrepreneur, mentor, and company builder, Michael leads the Recuro Health team which includes several leaders from Teladoc, where he served as the founding CEO and pioneered an industry-changing health care model that created a new efficiency paradigm in healthcare by delivering physicians to patients nationwide in under 12 minutes for $35.
Gorton ran Teladoc as CEO and Chairman for the first seven years of operations. Under his term, the company grew from a concept to one of the most recognized innovations in healthcare, with nearly two million patient members nationwide. Under the Teladoc model, physicians made more and patients paid less. Teladoc was studied and advocated by most of the major healthcare think tanks and was recently named one of the most innovative companies in healthcare. Teladoc recently entered the NYSE and now has a market cap of over $30B.
Michael’s decades of experience as a strategic visionary, impacting the telecommunications, music and healthcare industries include a leadership role as a founder of Principal Solar where he applied his business expertise, scientific education and training to the renewable energy sector -- a strong voice and proponent of solar power.
He has served as a partner of the Texas Acceleration Group (TAG), an entity formed to assist startup companies and participated as a founder of Palo Duro Records. He is also credited as a founder of Internet Global, a company that delivered the first DSL network and one of the first VOIP networks. Prior to this, he worked as a project engineer at Dallas Power & Light dealing with power plants, distribution, transformer management and integration of renewable energy into the grid.
Michael earned a B.S. in engineering from Texas Tech, an M.S. in Physics from the University of Texas at Dallas and a Juris Doctorate from Texas A&M.
Website: https://www.recurohealth.com
Social Media Links: Facebook: https://facebook.com/RecuroHealthLinkedin: https://linkedin.com/company/recuro-healthTwitter: https://twitter.com/RecuroHealth
Thursday Jul 15, 2021
Thursday Jul 15, 2021
Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:
What is Plus Therapeutics, and what is its mission?
Tell us about your background and what brought you to Plus Therapeutics?
What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
How could RNL help advance current treatment options for GBM and why is this important for patients?
Do you think most people understand radiation and its potential benefits as a cancer therapy?
What do you think is the most common misconception that people hold about radiation as a cancer treatment?
What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?
Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Website: plustherapeutics.com
Social Media Links: Facebook: facebook.com/plustherapeutics Instagram: instagram.com/plustherapeutics Twitter: twitter.com/plustxinc Linkedin: linkedin.com/company/plustherapeutics
Monday Jun 28, 2021
Monday Jun 28, 2021
Dr. Paul MacKoul, the Co-founder of The Center for Innovative G-Y-N Care, a minimally invasive G-Y-N Surgical Practice for treatment of fibroids, endometriosis and pelvic pain joins eHealth Radio and the Female Health and Health News Channels.
Listen to interview with host Eric Michaels & guest Dr. Paul MacKoul discuss the following:
What are the benefits of performing a GYN surgery in an ASC versus a Hospital setting?
Why should a woman see a GYN Specialist versus having a procedure done with her OBGYN?
What are the biggest challenges clinicians face when performing a myomectomy?
How does the CIGC laparoscopic approach to myomectomy help minimize complications and achieve positive outcomes for patients?
How has the pandemic impacted your practice and what are you anticipating you will see in 2022?
Paul J. MacKoul, MD, is board certified in gynecology and fellowship trained in gynecologic oncology. He is a specialist in the minimally invasive treatment of complex GYN conditions such as fibroids, ovarian masses and endometriosis, as well as early-stage GYN cancer.
Along with Natalya Danilyants, MD, he founded The Center for Innovative GYN Care®. Dr. MacKoul and Dr. Danilyants developed and perfected the DualPortGYN® and LAAM® surgical techniques performed at CIGC®. He has presented at major national meetings and been published in respected medical journals. He is frequently sought as a medical expert on techniques for minimally invasive removal of noncancerous, precancerous and cancerous tumors.
Dr. MacKoul has served as director of gynecologic laparoscopy at Holy Cross Hospital and as director of GYN oncology at George Washington University Hospital and Washington Hospital Center, as well as on the faculty of George Washington University Hospital. Dr. MacKoul graduated from medical school at Tufts University and completed his residency in obstetrics and gynecology at the University of Maryland. His fellowship in gynecologic oncology was at the University of North Carolina. He was named a Center of Excellence in Minimally Invasive Gynecology Designated Surgeon in 2012.
Dr. MacKoul is CEO of Tower Surgical Partners, an ASC management company that oversees three surgery centers and four practice offices in Maryland, Virginia, New York and New Jersey.
Website: www.innovativegyn.com
Social Media Links: Facebook: facebook.com/Innovativegyncare Instagram: instagram.com/innovativegyn LinkedIn: linkedin.com/company/the-center-for-innovative-gyn-care Twitter: twitter.com/innovativegyn YouTube: youtube.com/c/TheCenterforInnovativeGYNCare/videos
Wednesday Sep 09, 2020
Wednesday Sep 09, 2020
Robert Schlein, the Founder of Buddy Custard, the first frozen treat for dogs that acts as a neutraceutical for pets joins eHealth Radio and the Animal Health Channel.
Listen to interview with host Eric Michaels and guest Robert Schlein discuss the following:
What is Buddy Custard and for what kind of pet?
I understand you founded Buddy Custard based on a similar protocol you followed that has left you cancer free. What was that protocol and how did it inspire you create Buddy Custard?
How do you use Buddy Custard for your pets – is it an additive or a stand alone frozen treat?
Can Buddy Custard in any way harm my dog?
Do you have plans to expand the line for other pets including cats?
TIP: You can control the health and wellness of your dog –even if they may have cancer – if you have the right formula – Buddy Custard saves lives of Dogs.
Robert Schlien is the Founder and CEO of Buddy Custard Inc. Robert is a cancer survivor of 13 years and had the good fortune of being introduced to the Budwig Protocol seven years ago. At that time, he had already decided to forego the conventional treatment of chemotherapy prescribed to him. Instead he employed this simple, sensible technology. It is his own personal experience that inspired he and co-founder Katherine Schlein to use that protocol to develop Buddy Custard, a frozen treat additive to foods for dogs.
Robert's professional background includes extensive experience developing businesses worldwide from conception to public entity. He previously founded a diet and wellness program (Lifestyle Slim Inc.), and has been instrumental in the acquisition and growth of many private and public ventures.
Website: www.buddycustard.com
Social Media Links: Facebook: facebook.com/buddycustardco Instagram: instagram.com/buddycustard Twitter: twitter.com/buddycustard
Friday Apr 24, 2020
Friday Apr 24, 2020
Dr. John Dobak, the President & CEO of DermTech, the leading genomics company in dermatology that is creating a new category of medicine, precision dermatology, enabled their non-invasive skin genomics platform joins eHealth Radio and the Dermatology and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. John Dobak discuss the following:
Precision medicine is a leading innovation. Can you tell us about Precision Dermatology and what that means?
What is the value of genomics in dermatology?
How does this non-invasive test have the potential to shift the melanoma detection landscape?
How does the DermTech PLA work?
Are you adapting to the shift towards tele-medicine within the current environment? 6. What is next for DermTech? Are there other applications of this technology?
Dr. John Dobak, MD, has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.
Website: dermtech.com
Social Media Links: Twitter: twitter.com/DermTech Instagram: instagram.com/dermtech Facebook: facebook.com/dermtech Linkedin: linkedin.com/company/dermtech
Thursday Mar 12, 2020
Thursday Mar 12, 2020
When Bilal Qizilbash (B.S. in biology, M.S. in medical sciences) discovered that juiced leafy kale would selectively kill melanoma cancer cells in vitro while leaving non-cancerous cells alone, he’d had a breakthrough and a realization that there was an opportunity to help humanity by developing a product that makes it easy and unintimidating for people to add kale to their diets.
As the CEO of EasyKale Labs, he's continuing his research into the cancer-fighting properties of kale, while offering a next-generation product for making kale consumption easier: Bilal's EasyKale® and joins eHealth Radio and the Health News and Cancer Prevention Channel to discuss.
Listen to interview with host Eric Michaels & guest Bilal Qizilbash discuss the following:
Why is a product like EasyKale necessary?
What makes you so passionate about helping people through your work with EasyKale?
How can EasyKale help those in need, especially in “food deserts?”
What can we expect from EasyKale Labs in 2020?
As the CEO of EasyKale Labs, Qizilbash is continuing his research into the cancer-fighting properties of kale, while offering a next-generation product for making kale consumption easier: Bilal's EasyKale®.
Qizilbash has presented lectures on leadership, innovation, and his team's cancer breakthrough at numerous conferences, most notably at the Global Health & Innovation Conference at Yale University attended by over 3,000 people.
Along with his scientific research and CEO duties, Bilal Qizilbash is a social entrepreneur with a passion for feeding the hungry in his adopted home town of Jackson, Mississippi, through his non-profit organization, the Draw a Smile Foundation.
Bilal pledges 2.5% of net profits from the sale of Bilal's EasyKale to the Draw-a-Smile Foundation and another 2.5% of net profits to the Mississippi Coding Academies, a passion project for Bilal's co-founder, Rich Sun, helping at-risk kids build technology careers.
Website: http://easykale.com
Social Media Links: Facebook: https://www.facebook.com/easykaleshaker Twitter: https://twitter.com/BilalQizilbash
Monday Nov 11, 2019
Monday Nov 11, 2019
Dr. Michael Molyneaux, Chief Medical Officer of Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels & guest Dr. Michael Molyneaux discuss the following:
Can you tell us about your background?
What is Sirnaomics? Can you provide us with a background of the company and its current disease indication focus?
What are some available treatments for non-melanoma skin cancer?
How are RNA-based therapeutics different than DNA-based medicine?
What are some drawbacks to RNAi-based therapy?
What is Sirnaomics doing to address these challenges?
What should people keep in mind when thinking about cancer treatment?
Dr. Michael Molyneaux, M.D., MBA & Chief Medical Officer of Sirnaomics brings a unique background with 20 years of experience in clinical medicine and direct patient care combined with 15 years of experience in clinical trial development. Mike is a board certified Medical Doctor and has completed his MBA. He was previously the CMO of Macrocure, a late stage clinical company that completed successful IPO in fall of 2014. Mike’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for Global Clinical Operations, Regulatory Affairs, and Medical Affairs. Mike is also a member of the Sirnaomics Board of Directors.
Website: https://sirnaomics.com
Social Media Links: LinkedIn: linkedin.com/company/sirnaomics-inc Facebook: facebook.com/sirnaomics
Friday Oct 04, 2019
Friday Oct 04, 2019
Rick Fair, President & CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment joins eHealth Radio & the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels & guest Rick Fair discuss the following:
How does CAR-T cancer therapy compare to standard cancer treatments?
What are some of the drawbacks to CAR-T Therapy?
What is Bellicum doing to address these challenges?
What should people keep in mind when thinking about cancer treatment?
Rick Fair is the President and CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment.
Prior to joining Bellicum, Mr. Fair served as the Senior Vice President, Head of Oncology Global Product Strategy at Genentech/Roche, where he led oncology product strategy and global commercialization. He also oversaw the global launch of five new cancer treatments, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine.
Prior to Genentech, Mr. Fair spent nine years at Johnson & Johnson, where he held leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.
Website: bellicum.com
Social Media Links: Facebook: facebook.com/pages/Bellicum-Pharmaceuticals-IncTwitter: @BellicumPharma
Saturday Jul 27, 2019
Saturday Jul 27, 2019
Hugh Woodward, an expert on DHEA & the President of Health2Go that researches and develops leading edge anti-aging and wellness products and provides them to people conveniently and cost effectively joins eHealth Radio and the Health News and Supplement Channels to discuss how to maintain your hormones to feel and look your best.
Listen to interview with host Eric Michaels & guest Hugh Woodward discuss the following:
What is DHEA?
Why is it so important to maintain healthy DHEA levels?
I understand DHEA has many beneficial effects, share with us some of those.
Why use DHEA as an absorbable cream supplement rather than a pill?
What is Twist 25 DHEA cream?
Hugh Woodward has a management degree and a Masters of Science in Health Administration. Hugh is a subject matter expert on DHEA having studied it for the past 14 years of his life studying the medical research about it, and starting a company to research, develop a safe effective DHEA supplement cream possible and distributing it.
In 2007 Mr. Woodward started Health2Go, Inc. to research and develop leading edge science based anti-aging and wellness products and bring them to customers conveniently and cost effectively. His father John Woodward a highly respected Medical Doctor invented Twist 25 DHEA cream.
Websites: twist25.com | store.twist25.com | blog.twist25.com
Social Media Links: Facebook: facebook.com/Twist25DHEACream Youtube: youtube.com/watch?v=LUhqm6Ayt0U